ArticleCureus2025
Porphyria Cutanea Tarda: A Multifactorial Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porphyria cutanea tarda (PCT) is a disorder characterized by porphyrin accumulation leading to photosensitivity and skin fragility, often triggered by a combination of genetic, autoimmune, and environmental factors. This case describes a 39-year-old woman with primary Sjögren syndrome (pSS) and heterozygosity for the HFE H63D mutation who developed PCT following hydroxychloroquine (HCQ) therapy. Initial symptoms included xerostomia, fatigue, and skin lesions. Laboratory tests showed liver enzyme elevation, leukopenia, hyperferritinemia, and positive anti-SSA/SSB antibodies. Hydroxychloroquine-induced hepatotoxicity prompted treatment discontinuation, and porphyrin analysis confirmed PCT. Despite the absence of UROD gene mutations, the interplay between pSS, iron overload, and medication exposure supported a diagnosis of sporadic PCT. The patient was successfully managed with low-dose HCQ for porphyrin clearance and azathioprine for autoimmune disease control. This case highlights the importance of recognizing multifactorial contributors in PCT and tailoring treatment accordingly to avoid complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.